Status:
NOT_YET_RECRUITING
Predictive Value of CEA and ctDNA in Lung Cancer Recurrence
Lead Sponsor:
Guangdong Provincial People's Hospital
Conditions:
Lung Carcinoma
Eligibility:
All Genders
15-100 years
Brief Summary
The study aims to investigate the predictive value of CEA levels for postoperative recurrence in the highly sensitive CEA lung cancer patients and to explore whether the dynamic changes of postoperati...
Detailed Description
This study will collect two groups of cohorts: prospective and retrospective.
Eligibility Criteria
Inclusion
- Preoperative CEA \> 5mg/l
- MRD testing was conducted before the operation
- The primary lesion was resected through surgery
- There should be at least two CEA and MRD follow-up tests within 2 years after the operation
- Postoperative pathology confirmed it as a malignant lung tumor
Exclusion
- Those without available imaging records
- Patients with a history of malignant tumors within the past five years
- Patients with secondary lung cancer
Key Trial Info
Start Date :
September 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07170046
Start Date
September 15 2025
End Date
August 1 2027
Last Update
September 12 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.